TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET INTRODUCTION

2.1. Definition

2.2. Scope of the Study

2.2.1. Research Objective

2.2.2. Assumptions

2.2.3. Limitations

3. RESEARCH METHODOLOGY

3.1. Overview

3.2. Data Mining

3.3. Secondary Research

3.4. Primary Research

3.4.1. Primary Interviews and Information Gathering Process

3.4.2. Breakdown of Primary Respondents

3.5. Forecasting Model

3.6. Market Size Estimation

3.6.1. Bottom-Up Approach

3.6.2. Top-Down Approach

3.7. Data Triangulation

3.8. Validation

4. MARKET DYNAMICS

4.1. Overview

4.2. Drivers

4.3. Restraints

4.4. Opportunities

5. MARKET FACTOR ANALYSIS

5.1. Value Chain Analysis

5.2. Porter’s Five Forces Analysis

5.2.1. Bargaining Power of Suppliers

5.2.2. Bargaining Power of Buyers

5.2.3. Threat of New Entrants

5.2.4. Threat of Substitute

5.2.5. Intensity of Rivalry

5.3. COVID-19 Impact Analysis

5.3.1. Market Impact Analysis

5.3.2. Country Impact

5.3.3. Opportunity and Threat Analysis

6. JAPAN AESTHETICS MARKET, BY PRODUCT

6.1. Overview

6.2. Facial Aesthetics

6.3. Body Contouring

6.4. Cosmetic Implants

6.5. Physician-dispensed Cosmeceuticals

6.6. Skin Aesthetics

7. JAPAN AESTHETICS MARKET, BY PROCEDURE TYPE

7.1. Overview

7.2. Invasive Procedures

7.3. Non-invasive Procedures

8. JAPAN AESTHETICS MARKET, BY COUNTRY

8.1. Overview

8.2. Japan

9. COMPETITIVE LANDSCAPE

9.1. Overview

9.2. Competitive Analysis

9.3. Market Share Analysis

9.4. Major Growth Strategy in the Japan Aesthetics Market,

9.5. Competitive Benchmarking

9.6. Leading Players in Terms of Number of Developments in the Japan Aesthetics Market,

9.7. Key developments and Growth Strategies

9.7.1. New Product Launch/Service Deployment

9.7.2. Merger & Acquisitions

9.7.3. Joint Ventures

9.8. Major Players Fnancial Matrix

9.8.1. Sales & Operating Income, 2022

9.8.2. Major Players R&D Expenditure. 2022

10. COMPANY PROFILES

10.1. Galderma SA

10.1.1. Company Overview

10.1.2. Financial Overview

10.1.3. Sientra, Inc.

10.1.4. Key Developments

10.1.5. SWOT Analysis

10.1.6. Key Strategies

10.2. Merz Pharma GmbH & Co. KGaA

10.2.1. Company Overview

10.2.2. Financial Overview

10.2.3. Products Offered

10.2.4. Key Developments

10.2.5. SWOT Analysis

10.2.6. Key Strategies

10.3. Syneron Medical Ltd.

10.3.1. Company Overview

10.3.2. Financial Overview

10.3.3. Products Offered

10.3.4. Key Developments

10.3.5. SWOT Analysis

10.3.6. Key Strategies

10.4. Cynosure, Inc ..

10.4.1. Company Overview

10.4.2. Financial Overview

10.4.3. Products Offered

10.4.4. Key Developments

10.4.5. SWOT Analysis

10.4.6. Key Strategies

10.5. Cutera, Inc

10.5.1. Company Overview

10.5.2. Financial Overview

10.5.3. Products Offered

10.5.4. Key Developments

10.5.5. SWOT Analysis

10.5.6. Key Strategies

10.6. Lumenis Ltd

10.6.1. Company Overview

10.6.2. Financial Overview

10.6.3. Products Offered

10.6.4. Key Developments

10.6.5. SWOT Analysis

10.6.6. Key Strategies

10.7. Valeant Pharmaceuticals International, Inc..

10.7.1. Company Overview

10.7.2. Financial Overview

10.7.3. Products Offered

10.7.4. Key Developments

10.7.5. SWOT Analysis

10.7.6. Key Strategies

11. APPENDIX

11.1. References

11.2 Related Reports